Round Rock Advisors »

Protalix Biotherapeutics shares owned by Round Rock Advisors

Quarter-by-quarter ownership of Protalix Biotherapeutics (PLX) shares owned by Round Rock Advisors from 13F filings

Historical chart of Round Rock Advisors investment in Protalix Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protalix Biotherapeutics held by Round Rock Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protalix Biotherapeutics by Round Rock Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $279k 155k 1.80

More positions owned by Round Rock Advisors

Invesco Qqq Tr Unit Ser 1 (QQQ)
J P Morgan Exchange Traded F Ultra Shrt Etf (JPST)
Vanguard Whitehall Fds High Div Yld (VYM)
Vaneck Etf Trust Semiconductr Etf (SMH)
Ishares Tr Core S&p Scp Etf (IJR)
Vanguard Index Fds Mid Cap Etf (VO)
Apple (AAPL)
Select Sector Spdr Tr State Street Ind (XLI)
Select Sector Spdr Tr State Street Hea (XLV)
Ishares Tr Select Divid Etf (DVY)
Microsoft Corporation (MSFT)
Berkshire Hathaway Inc Del Cl A (BRK.A)
American Centy Etf Tr Short Durtn Strg (SDSI)
Alphabet Cap Stk Cl C (GOOG)
Neuberger Berman Etf Trust Short Duration I (NBSD)

View all positions for Round Rock Advisors

Top funds holding Protalix Biotherapeutics

BlackRock
Opaleye Management
Renaissance Technologies
Northern Trust
Geode Capital Management
State Street Corporation
Stratos Wealth Partners
Vanguard Group
Jane Street
Goldman Sachs Group
UBS Group
Connor, Clark & Lunn Investment Management
Main Street Financial Solutions
Bank of New York Mellon
Bridgeway Capital Management

View all funds holding Protalix Biotherapeutics